BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24249660)

  • 21. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
    Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing paradigm of chronic lymphocytic leukemia management.
    Lobetti-Bodoni C; Bertoni F; Stussi G; Cavalli F; Zucca E
    Eur J Intern Med; 2013 Jul; 24(5):401-10. PubMed ID: 23583413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
    Witzig TE; Weitz JJ; Lundberg JH; Tefferi A
    Leuk Lymphoma; 1994 Jun; 14(1-2):137-9. PubMed ID: 7920220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pentostatin treatment combinations in chronic lymphocytic leukemia.
    Lamanna N; Kay NE
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):386-92. PubMed ID: 19606074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
    Schierl M; Foedinger D; Geissler K; Rappersberger K; Feldmann R
    Eur J Dermatol; 2008; 18(6):717-8. PubMed ID: 19049939
    [No Abstract]   [Full Text] [Related]  

  • 26. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
    Molica S
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1333-40. PubMed ID: 21929307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
    J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
    Ettahar N; Legout L; Ajana F; Patoz P; Massongo M; Rose C; Senneville E
    J Mycol Med; 2013 Mar; 23(1):57-63. PubMed ID: 23375857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal failure secondary to leukemic infiltration of kidneys in CLL--a case report and review of literature.
    Uprety D; Peterson A; Shah BK
    Ann Hematol; 2013 Jan; 92(2):271-3. PubMed ID: 22875063
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.
    Kourelis TV; Kahl BS; Benn P; Delach JA; Bilgrami SF
    Acta Haematol; 2011; 126(1):40-3. PubMed ID: 21430370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
    Borthakur G; O'Brien S; Wierda WG; Thomas DA; Cortes JE; Giles FJ; Kantarjian HM; Lerner S; Keating MJ
    Br J Haematol; 2007 Mar; 136(6):800-5. PubMed ID: 17341265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
    J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
    Cervigón I; Palomo A; Torres-Iglesias LM; Solano F; Zapata AM
    Actas Dermosifiliogr; 2011 May; 102(4):305-7. PubMed ID: 21354544
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
    Panovská A; Smolej L; Lysák D; Brychtová Y; Šimkovič M; Motyčková M; Vodárek P; Lindtnerová M; Trbušek M; Malčíková J; Pospíšilová Š; Mayer J; Doubek M
    Eur J Haematol; 2013 Jun; 90(6):479-85. PubMed ID: 23506191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
    Vardi A; Vlachonikola E; Papazoglou D; Psomopoulos F; Kotta K; Ioannou N; Galigalidou C; Gemenetzi K; Pasentsis K; Kotouza M; Koravou E; Scarfó L; Iskas M; Stavroyianni N; Ghia P; Anagnostopoulos A; Kouvatsi A; Ramsay AG; Stamatopoulos K; Chatzidimitriou A
    Clin Cancer Res; 2020 Sep; 26(18):4958-4969. PubMed ID: 32616500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.